NanoViricides Advances Broad-Spectrum Antiviral Drug, Eyes Multiple Phase II Trials
NanoViricides is progressing its NV-387 drug candidate across multiple viral infections, with pending Phase II trials for MPox and emerging programs for measles and avian flu, highlighting significant potential in antiviral treatment development.
NanoViricides, a development-stage biotechnology company, is making substantial strides in its antiviral drug development program with NV-387, a broad-spectrum therapeutic candidate targeting multiple viral infections.
The company has received clearance from the Democratic Republic of Congo's National Ethics Committee to submit a Phase II trial application for MPox, marking a significant milestone in its research pipeline. Concurrently, NanoViricides is initiating development programs targeting measles and avian flu, expanding the potential applications of its drug candidate.
NV-387 has demonstrated promising results in preclinical studies, completing Phase I trials without adverse events and showing superior activity in animal models compared to currently approved antivirals for COVID-19, influenza, respiratory syncytial virus (RSV), and smallpox.
Despite these advances, the company faces financial challenges. With $2.73 million in cash and $6.98 million in property and equipment, NanoViricides acknowledges the need for additional funding to support operations beyond early 2026.
The potential impact of NV-387 extends across multiple viral diseases, offering hope for more effective antiviral treatments. By developing a broad-spectrum drug that could address various viral infections, NanoViricides is positioning itself at the forefront of innovative antiviral therapeutic research.